Sirnaomics

Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development

by

HONG KONG, Germantown, Md. and SUZHOU, China, July 27, 2023  /PRNewswire/ — Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that Dr. Francois Lebel, M.D., an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the … Read more

Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development

by

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 19, 2023 /PRNewswire/ — Sirnaomics Ltd. (the “Company”; stock code: 2257, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the advancement of STP705 for the treatment of Squamous Cell Carcinoma in situ (isSCC) into late-stage … Read more

Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences

by

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 13, 2023 /PRNewswire/ — Sirnaomics Ltd. (the “Company”; stock code: 2257, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that the Company will present the latest developments on GalAhead™, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at three … Read more

Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty

by

HONG KONG, GERMANTOWN, Md. and SUZHOU, China , June 5, 2023 /PRNewswire/ — Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced the interim results of an ongoing Phase I clinical trial of STP705, an siRNA (small interfering RNA) … Read more

Sirnaomics to receive HK$8 million subsidy from the HKSTP Clinical Translational Catalyst Plan

by

HONG KONG and GERMANTOWN, Md. and SUZHOU BIOBAY, China, May 17, 2023 /PRNewswire/ — Sirnaomics Ltd. (the “Company”; together with its subsidiaries, the “Group” or “Sirnaomics”; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has received approval of an HK$8 million subsidy from the Hong Kong Science and Technology Parks Corporation … Read more